Abstract
Thirty-one patients with stage IIIA (N2) non-small-cell lung cancer were randomized to receive radiotherapy alone or chemotherapy with cisplatin and vinblastine followed by surgery. Response rates to induction chemotherapy and radiotherapy were 50% and 53.3% respectively. Complete surgical resection was possible for 62.5% of patients. Median survival times were 16.2 and 18.7 months for radiotherapy alone and chemotherapy-surgery respectively (P = Ns), with no long-term improvement in survival seen with combined-modality treatment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Pass H. I., Pogrebniak H. W., Steinberg S. M., Mulshine J., Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun;53(6):992–998. doi: 10.1016/0003-4975(92)90373-c. [DOI] [PubMed] [Google Scholar]
- Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., Mate J. L., Li S., Roig J., Olazábal A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153–158. doi: 10.1056/NEJM199401203300301. [DOI] [PubMed] [Google Scholar]
- Sause W. T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., Emami B., Curran W. J., Byhardt R. W., Turrisi A. T. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995 Feb 1;87(3):198–205. doi: 10.1093/jnci/87.3.198. [DOI] [PubMed] [Google Scholar]
- Shepherd F. A. Induction chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg. 1993 Jun;55(6):1585–1592. doi: 10.1016/0003-4975(93)91123-5. [DOI] [PubMed] [Google Scholar]